ADELAIDE, Australia and CAMBRIDGE, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (NASDAQ:BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced that it will be presenting at the 2024 BIO CEO & Investor Conference taking place February 26-27, 2024 in New York, NY.
Spyros Papapetropoulos, M.D., Ph.D., President and CEO of Bionomics will be providing an update on the Company's leading asset, BNC210, a Phase 3 ready, first- and best-in-class ?7 nicotinic receptor negative allosteric modulator in development for the treatment of social anxiety disorder and post-traumatic stress disorder.
Presentation information
Day and date: Tuesday, February 27, 2024
Time: 10:15 AM EST
Location: New York Marriott Marquis – Plymouth Room
For those interested in meeting Bionomics' management during the conference, please request a meeting through the conference portal or contact the Company's Investor Relations.
FOR FURTHER INFORMATION PLEASE CONTACT:
General Rajeev Chandra Company Secretary CoSec@bionomics.com.au | Investor Relations Kevin Gardner |